Immunosuppression Practices in Liver Transplantation: A Survey of North American Centers

Exp Clin Transplant. 2018 Oct;16(5):550-553. doi: 10.6002/ect.2017.0096. Epub 2017 Aug 28.

Abstract

Objectives: There is a clear lack of clinical evidence guiding immunosuppressive management in long-term stable liver transplant recipients. As a result, anecdotal experience suggests wide variability across transplant centers. We aimed to identify patterns of immunosuppression practices in liver transplant centers across Canada and the United States.

Materials and methods: From February 9 to May 31, 2015, we invited clinicians from all liver transplant centers in Canada and the United States to answer a 6-question survey generated using SurveyMonkey.

Results: Seventeen respondents from 15 liver transplant centers completed the survey. Although immun-suppressive practices are relatively uniform for induction and early maintenance therapy, significant variations exist in the management of long-term immunosuppression in stable transplant recipients with a relative lack of minimization protocols.

Conclusions: Our survey confirms a wide variability in immunosuppression practices across Canadian and US liver transplant centers. Research and practice priorities include design of pragmatic randomized controlled trials and development of clinical practice guidelines to standardize immunosuppressive management of long-term stable liver transplant recipients with a focus on immunosuppression minimization.

MeSH terms

  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • Graft Survival / drug effects*
  • Health Care Surveys
  • Healthcare Disparities / trends
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Liver Transplantation / adverse effects
  • Liver Transplantation / trends*
  • North America
  • Practice Patterns, Physicians' / trends*
  • Time Factors
  • Treatment Outcome

Substances

  • Immunosuppressive Agents